Recent News

FDA Accepts Biologics License Application for Isatuximab in Resistant Multiple Myeloma

EHA24 Congress: Selinexor With Daratumumab and Dexamethasone in Resistant Myeloma

FDA Grants Accelerated Approval to Selinexor Combination for Resistant Myeloma

Addition of Isatuximab to Pomalidomide/Dexamethasone in Multiple Myeloma

Partial Clinical Hold Lifted by FDA on Venetoclax Study in Multiple Myeloma

FDA Approves Daratumumab Combination for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma

EHA24 Congress: Melflufen Combination Regimen for Resistant Multiple Myeloma

ICML 2019: Is Triplet Induction Therapy Safe for Older Patients With Multiple Myeloma?

EHA24 Congress: Novel Agent Under Study in Combination Therapies for Myeloma

EHA24 Congress: Daratumumab Plus Standard Therapy in Newly Diagnosed Myeloma

EHA24 Congress: Venetoclax Combination Therapy in Resistant Myeloma

ASCO 2019: Adding Daratumumab to Standard of Care in Transplant-Eligible Newly Diagnosed Myeloma

Daratumumab Combination Therapy Granted Priority Review in Multiple Myeloma

ASCO 2019: Predicting Early Relapse in Patients With Myeloma Treated With Triplet Regimens

ASCO 2019: Impact of Insurance Type on Survival in Multiple Myeloma

ECT-001 Granted Regenerative Medicine Advanced Therapy Designation for Treatment of Hematologic Malignancies

Evaluating Adherence to Immunomodulatory Drugs in Multiple Myeloma

FDA Grants Fast Track Designation for CLR 131 in Multiple Myeloma

ASCO 2019: Lenalidomide vs. Observation in Smoldering Multiple Myeloma

Immunoglobulin Lambda Translocation and Treatment Resistance in Multiple Myeloma

Multiple Myeloma Research Foundation Launches Investment Fund to Advance New Therapies

Novel Selective HDAC6 Inhibitor Under Study in Multiple Myeloma

Severe Obesity and Outcomes After Transplant for Myeloma

Allogeneic CAR T-Cell Therapy to Enter Phase I Trial in Multiple Myeloma

Role of Mesenchymal Stem Cells in Progression of Multiple Myeloma

FDA Warns of Risks Associated With Investigational Use of Venetoclax in Multiple Myeloma

Real-World Findings With Ixazomib, Lenalidomide, and Dexamethasone in Multiple Myeloma

Modeling Renal Injury in Multiple Myeloma

Challenges in Precision Medicine Strategies in Multiple Myeloma

Perlmutter Cancer Center Receives Anonymous Gift of $75 Million for New Blood Cancer Center

Does Intensive Therapy Improve Survival in Patients With Multiple Myeloma?

Daratumumab Split-Dosing Regimen for Multiple Myeloma Approved by the FDA

Researchers Launch Study of Precursor Conditions of Multiple Myeloma

African Ancestry and Genetic Alterations Leading to Multiple Myeloma

European Commission Approves Split-Dose of Daratumumab in Multiple Myeloma

Quadruplet Versus Triplet Therapy for Multiple Myeloma